Clostridioides difficile infection (CDI) is a leading cause of healthcare-associated diarrhea worldwide, posing significant risks of morbidity and mortality1 . It often occurs after antibiotic use, which disrupts normal gut bacteria, allowing C. difficile to proliferate and produce toxins that cause symptoms ranging from mild diarrhea to life-threatening colitis2 . Preventing recurrence remains a major challenge, with about 25% of patients experiencing repeat infection after an initial episode and up to 60% after multiple recurrences3 . Optimal treatment depends on disease severity, prior infection history, and individual risk factors for recurrence4 .
Treatment Options by Stage
Treatments for Nonsevere C. Diff Infection
Nonsevere CDI typically presents with watery diarrhea, abdominal cramping, and mild systemic symptoms without signs of organ dysfunction5 . Diagnosis requires at least three unformed stools in 24 hours and positive stool tests for C. difficile toxins or the organism6 . Treatment aims to eradicate the infection while preserving the gut microbiome.
Current guidelines recommend oral fidaxomicin or oral vancomycin as first-line agents for initial nonsevere CDI7 89. Fidaxomicin is preferred due to its narrower spectrum and lower recurrence rates, but vancomycin remains an acceptable alternative, especially where cost or access to fidaxomicin is limited10 11. Metronidazole is now reserved for settings where these agents are unavailable or for mild cases due to lower efficacy and higher recurrence risk4 11.
- Fidaxomicin: 200 mg orally twice daily for 10 days12 .
- Vancomycin: 125 mg orally four times daily for 10 days13 .
- Metronidazole: oral administration for mild disease only, typically 500 mg three times daily for 10 days4 .
Stopping the inciting antibiotic, if possible, is crucial to reduce ongoing disruption of gut flora and improve treatment success5 . Supportive care includes hydration and nutrition, emphasizing starchy foods to prevent nutrient loss during diarrhea14 .
Treatments for Severe C. Diff Infection
Severe CDI is characterized by a white blood cell count greater than 15,000 cells/mL or serum creatinine ≥1.5 mg/dL, indicating systemic inflammation and potential organ involvement5 . Patients may have more frequent diarrhea, fever, and abdominal tenderness.
Treatment for severe CDI prioritizes oral vancomycin or fidaxomicin, with vancomycin often preferred due to broader availability and experience8 913. Metronidazole is no longer recommended as monotherapy for severe disease but may be added intravenously if ileus (intestinal paralysis) is present5 . Early diagnosis and appropriate therapy reduce complications such as pseudomembranous colitis and toxic megacolon2 .
- Oral vancomycin: 125 mg four times daily for 10 days13 .
- Fidaxomicin: 200 mg twice daily for 10 days12 .
- Intravenous metronidazole may be added if ileus or severe systemic symptoms occur5 .
An interdisciplinary team approach is recommended for critically ill patients to monitor for complications and adjust therapy promptly15 .
Treatments for Fulminating Colitis
Fulminant colitis is a life-threatening form of CDI marked by hypotension, shock, ileus, or toxic megacolon5 . This stage requires urgent and aggressive treatment.
Oral vancomycin remains the cornerstone of therapy, administered at higher doses (500 mg orally four times daily) and combined with intravenous metronidazole to maximize antimicrobial coverage13 . If ileus prevents oral intake, vancomycin can be administered via a nasogastric tube or rectal enemas5 . Early surgical consultation is critical, as subtotal colectomy with rectal preservation may be needed for patients with severe colonic damage or perforation15 13.
- Vancomycin: 500 mg orally or via tube four times daily13 .
- Metronidazole: 500 mg intravenously every 8 hours5 .
- Surgery: subtotal colectomy for refractory or complicated cases15 .
Close monitoring in an intensive care setting is essential to manage organ dysfunction and prevent mortality16 .
Treatments for Recurring Symptoms
Recurrence of CDI is common, affecting approximately 25% of patients after the first episode and up to 60% after multiple recurrences3 13. Recurrence risk factors include older age, ongoing antibiotic use, immunosuppression, and severe underlying illness13 .
“Either vancomycin or fidaxomicin is recommended over metronidazole for an initial episode of Clostridioides difficile infection (CDI). The dosage is vancomycin 125 mg orally four times daily or fidaxomicin 200 mg twice daily for 10 days.”
— L Clifford McDonald, Infectious Diseases Society of America13
Management of recurrent CDI depends on the number of prior episodes and treatment history. For the first recurrence, fidaxomicin or a prolonged tapered and pulsed vancomycin regimen is recommended9 5. For multiple recurrences, fecal microbiota transplantation (FMT) is highly effective, restoring healthy gut bacteria and achieving cure rates above 85% 171318. Monoclonal antibody therapy with bezlotoxumab, targeting C. difficile toxin B, reduces recurrence risk when added to antibiotic treatment17 .
- First recurrence:
- Fidaxomicin standard or extended-pulsed dosing12 .
- Vancomycin tapered and pulsed regimen13 .
- Multiple recurrences:
- Fecal microbiota transplantation after at least two prior antibiotic-treated recurrences9 13.
- Bezlotoxumab adjunctive therapy to reduce recurrence17 .
Antibiotic stewardship is critical to prevent recurrence by minimizing unnecessary antibiotic exposure5 . Patients should be counseled on hygiene and infection control to reduce spread and reinfection19 .
“For fulminant Clostridioides difficile infection (CDI), oral vancomycin is the regimen of choice.”
— L Clifford McDonald, Infectious Diseases Society of America13
Managing C. Diff Infection
Effective management of CDI extends beyond antibiotic treatment to include accurate diagnosis, prevention of spread, and supportive care. Diagnosis requires the presence of diarrhea (three or more unformed stools in 24 hours) and laboratory confirmation of C. difficile toxins or the organism in stool samples6 5. Testing should be avoided in patients with formed stools or those without symptoms to prevent false positives6 .
Risk factors for CDI include recent antibiotic use, hospitalization, advanced age, immunocompromised status, and gastrointestinal surgery2 5. Patients with CDI should be isolated promptly, and healthcare workers must use gloves and gowns to prevent transmission2 . Environmental cleaning with sporicidal agents, such as bleach-based disinfectants, is essential to eliminate spores from surfaces20 .
Supportive care focuses on maintaining hydration and nutrition. Diarrhea can cause fluid and electrolyte losses, so patients should drink plenty of fluids and consume starchy foods like potatoes, rice, and oatmeal to maintain energy14 . Patients are advised to wash hands thoroughly with soap and water, as alcohol-based sanitizers are less effective against spores19 .
“Fecal microbiota transplantation is recommended for patients with multiple recurrences of Clostridioides difficile infection (CDI) who have failed appropriate antibiotic treatments.”
— L Clifford McDonald, Infectious Diseases Society of America13
Antibiotic stewardship is a key strategy to reduce CDI incidence and recurrence. Discontinuing or switching antibiotics that precipitated CDI can improve outcomes5 . Probiotics are not routinely recommended due to insufficient evidence of benefit5 .
Patients should be monitored for symptom resolution, and repeat stool testing after treatment is generally not recommended, as patients may continue to carry the bacteria without active infection5 19. Returning to normal activities is advised only after symptoms have resolved to prevent spread19 .
- Key management principles:
- Confirm diagnosis with appropriate stool testing only in symptomatic patients6 .
- Isolate infected patients and use contact precautions2 .
- Use sporicidal disinfectants for environmental cleaning20 .
- Provide supportive care with fluids and nutrition14 .
- Practice antibiotic stewardship to minimize recurrence risk5 .
Related Stories
Key Takeaways
- Clostridioides difficile infection is a major cause of healthcare-associated diarrhea with significant morbidity and mortality worldwide1 21.
- Treatment choice depends on disease severity, with fidaxomicin or vancomycin preferred for initial and severe infections; metronidazole is reserved for mild cases or when other agents are unavailable7 894.
- Fulminant colitis requires high-dose oral vancomycin plus intravenous metronidazole and often surgical intervention15 13.
- Recurrence is common; first recurrence is treated with fidaxomicin or tapered vancomycin, while multiple recurrences benefit from fecal microbiota transplantation and bezlotoxumab17 13.
- Managing CDI includes accurate diagnosis, infection control, supportive care, and antibiotic stewardship to reduce recurrence and transmission6 519.
